10x Genomics, Inc. — Director's Dealing 2021

Aug 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-08-03

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-03	Class A Common Stock	M	5208	$5.04	Acquired	909276	Direct
2021-08-03	Class A Common Stock	M	9792	$11.48	Acquired	919068	Direct
2021-08-03	Class A Common Stock	S	1700	$176.5203	Disposed	917368	Direct
2021-08-03	Class A Common Stock	S	4450	$177.5574	Disposed	912918	Direct
2021-08-03	Class A Common Stock	S	7946	$178.4706	Disposed	904972	Direct
2021-08-03	Class A Common Stock	S	904	$179.3464	Disposed	904068	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-03	Stock Option (right to buy)	$5.04	M	5208	Disposed	2028-11-02	Class A Common Stock (5208)	Direct
2021-08-03	Stock Option (right to buy)	$11.48	M	9792	Disposed	2029-05-10	Class A Common Stock (9792)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	89960	Indirect

Footnotes

F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $175.995 to $176.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $177.00 to $177.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $178.00 to $178.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $179.03 to $179.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F7: This option, originally for 250,000 shares, of which 175,843 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F8: This option, originally for 145,786 shares, of which 77,865 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.